Horizon Therapeutics (NASDAQ:HZNP) was upgraded by analysts at BMO Capital Markets from a “market perform” rating to an “outperform” rating in a report issued on Wednesday, The Fly reports.
Several other analysts have also issued reports on HZNP. BidaskClub lowered shares of Horizon Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, July 26th. Citigroup raised shares of Horizon Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $21.00 to $32.00 in a research report on Wednesday, May 1st. TheStreet lowered shares of Horizon Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, June 10th. Mizuho set a $27.00 price target on shares of Horizon Therapeutics and gave the company a “hold” rating in a research report on Wednesday, May 8th. Finally, Cowen set a $35.00 price target on shares of Horizon Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $32.09.
NASDAQ HZNP opened at $26.56 on Wednesday. The company has a 50 day simple moving average of $24.49. Horizon Therapeutics has a 12-month low of $16.56 and a 12-month high of $29.44. The company has a current ratio of 1.74, a quick ratio of 1.68 and a debt-to-equity ratio of 0.90. The company has a market capitalization of $4.89 billion, a price-to-earnings ratio of 14.51, a P/E/G ratio of 1.57 and a beta of 0.88.
Horizon Therapeutics (NASDAQ:HZNP) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.14. Horizon Therapeutics had a net margin of 5.90% and a return on equity of 32.71%. The company had revenue of $320.60 million for the quarter, compared to analyst estimates of $296.27 million. During the same quarter in the previous year, the firm posted $0.48 earnings per share. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. As a group, equities research analysts expect that Horizon Therapeutics will post 1.62 earnings per share for the current fiscal year.
In related news, EVP Geoffrey M. Curtis sold 20,609 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $26.58, for a total transaction of $547,787.22. Following the sale, the executive vice president now owns 28,382 shares of the company’s stock, valued at approximately $754,393.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jeff Kent sold 3,620 shares of the company’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $24.64, for a total transaction of $89,196.80. The disclosure for this sale can be found here. Insiders have sold a total of 48,480 shares of company stock worth $1,230,599 in the last ninety days. 4.10% of the stock is currently owned by insiders.
A number of institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc boosted its holdings in Horizon Therapeutics by 9.0% during the fourth quarter. Legal & General Group Plc now owns 73,686 shares of the biopharmaceutical company’s stock valued at $1,439,000 after purchasing an additional 6,054 shares in the last quarter. FMR LLC raised its stake in shares of Horizon Therapeutics by 361.8% in the fourth quarter. FMR LLC now owns 1,963,146 shares of the biopharmaceutical company’s stock valued at $38,360,000 after acquiring an additional 1,538,056 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Horizon Therapeutics by 8.9% in the fourth quarter. Geode Capital Management LLC now owns 1,935,457 shares of the biopharmaceutical company’s stock valued at $37,818,000 after acquiring an additional 158,342 shares during the last quarter. Calamos Advisors LLC raised its stake in shares of Horizon Therapeutics by 3.1% in the first quarter. Calamos Advisors LLC now owns 13,400 shares of the biopharmaceutical company’s stock valued at $354,000 after acquiring an additional 400 shares during the last quarter. Finally, Meeder Asset Management Inc. raised its stake in shares of Horizon Therapeutics by 74.4% in the first quarter. Meeder Asset Management Inc. now owns 17,343 shares of the biopharmaceutical company’s stock valued at $458,000 after acquiring an additional 7,396 shares during the last quarter. 87.83% of the stock is currently owned by institutional investors and hedge funds.
About Horizon Therapeutics
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Further Reading: LIBOR
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.